drugset / Trial / NCT01802970
Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients
NaSingle-groupOpen-labelTreatment
Summary
To determine the safety of administering anakinra plus the physician's chemotherapy choice (TPC) of nab paclitaxel, capecitabine, eribulin, or vinorelbine in patients with metastatic breast cancer (MBC), as well as determining blood immune cell transcriptional signatures in patients who undergo IL-1 receptor blockade.
Timeline
- Start
- 2012-12
- Primary completion
- 2017-01-04
- Completion
- 2017-01-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anakinra | Protein / enzyme biologic | 100 mg | Subcutaneous |
| Background | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Background | Eribulin | Small molecule | 1.4 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 100 mg/m2 | Intravenous |
| Background | Vinorelbine | Small molecule | 25 mg/m2 | — |